| Stereochemistry | RACEMIC |
| Molecular Formula | C14H22N2O2 |
| Molecular Weight | 250.3367 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCNC(=O)C(C)NC1=CC=C(OCC)C=C1
InChI
InChIKey=VVUMWAHNKOLVSN-UHFFFAOYSA-N
InChI=1S/C14H22N2O2/c1-4-10-15-14(17)11(3)16-12-6-8-13(9-7-12)18-5-2/h6-9,11,16H,4-5,10H2,1-3H3,(H,15,17)
| Molecular Formula | C14H22N2O2 |
| Molecular Weight | 250.3367 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Propetamide (also known as FC 379) is a propionamide derivative patented by All-Union Scientific Research Chemical-Pharmaceutical Institute as an analgesic compound. In mice, Propetamide produced both a depression of spontaneous motility and relaxation of muscular tone. However, Propetamide was less active than meprobamate. Propetamide at 400 mg/kg reduced muscular relaxation in 70% of the animals, while the same effect was obtained in 100% of the animals with meprobamate at 200 mg/kg.
Approval Year
PubMed
Patents
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
Showing 1 to 2 of 2 entries
